Propoxyphene withdrawal not a crisis, pharmacists say
- Dextropropoxyphene-containing analgesics cancelled. // WHO Drug Information;Jan2012, Vol. 26 Issue 1, p34
No abstract available.
- Consequences of dextropropoxyphene market withdrawal in elderly patients with chronic pain. Becquemont, Laurent; Delespierre, Tiba; Bauduceau, Bernard; Benattar-Zibi, Linda; Berrut, Gilles; Corruble, Emmanuelle; Danchin, Nicolas; Derumeaux, Geneviève; Doucet, Jean; Falissard, Bruno; Forette, Francoise; Hanon, Olivier; Pasquier, Florence; Pinget, Michel; Ourabah, Rissane; Bucher, Sophie; Lazkani, Aida; Piedvache, Celine; Bertin, Philippe // European Journal of Clinical Pharmacology;Oct2014, Vol. 70 Issue 10, p1237
Objective: Describe the consequences of dextropropoxyphene (DXP) market withdrawal on analgesic prescriptions and on the quality of therapeutic management of chronic pain. Patients and methods: From a cohort of non-institutionalised elderly patients with chronic pain recruited by general...
- Dextropropoxyphene: withdrawal. // WHO Drug Information;2010, Vol. 24 Issue 3, p215
The article discusses notices which several government agencies gave to health care professionals in New Zealand to remind them that the consent to distribute dextropropoxyphene containing medicines was revoked on August 1, 2010 and that it will no longer be legal to sell, distribute or...
- Propoxyphene: recommendation against use. // WHO Drug Information;2010, Vol. 24 Issue 4, p306
The article reports on a 2010 decision which the U.S. Food and Drug Administration made to recommend against the continued prescribing and use of the pain reliever propoxyphene because data showed that the drug can cause serious toxicity to the heart.
- Trusts will not be allowed to exclude drugs approved by NICE from formularies, says Lansley. Dyer, Clare // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/21/2012, Vol. 344 Issue 7840, p2
The article presents the suggestions of Michael Rawlins of the National Institute for Health and Clinical Excellence (NICE) that patients should take legal action over illegal refusals by Great Britain's National Health Service (NHS) healthcare providers to fund treatments approved by NICE.
- Cymbalta. // Pharmaceutical Representative;Dec2010, Vol. 40 Issue 12, p11
The article reports on the approval of Cymbalta from Eli Lilly & Co. for treating chronic musculoskeletal pain.
- Current FDA-Related Drug Information. . Baker, Danial E. // Hospital Pharmacy;Mar2010, Vol. 45 Issue 3, p253
Several tables are presented that provide information related to hospital pharmacy including the drugs that gain approval from the U.S. Food and Drug Administration (FDA) from December 18, 2009 to January 17, 2010, license applications filed by drug manufacturers and labeling changes.
- Dalbavancin is expected to have FDA approval soon. // Drug Formulary Review;May2008, Vol. 24 Issue 5, p39
The article reports that hospital pharmacies are expecting the availability of Pfizer Inc.'s potent antibiotic drug Dalbavancin after the U.S. Food and Drug Administration (FDA) sent a drug approval letter in late December 2007. Hospital pharmacies emphasized their willingness to stock the drug...
- Drug and Therapeutics Committee in Manipal Teaching Hospital, Pokhara, Nepal. Alam, Kadir; Palaian, Subish // Internet Journal of Pharmacology;2010, Vol. 9 Issue 1, p1
Drug use problems are common worldwide. Nepal is a developing country with several drug use problems. The Drug and Therapeutics committee (DTC) in Manipal Teaching Hospital (MTH) has been playing a vital role in promoting rational use of medicines in the hospital. The DTC has banned several...